Exclusive distribution agreement brings Point-Of-Care (POC) haematology diagnostics to new regions in the Middle East
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
GE Healthcare and Elekta aim to meet the major need for radiotherapy solutions across both developed and developing markets
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
The fund has already invested in seven companies including Medikabazaar, THB, Impact Guru, Stanplus, Ekincare, Qure.ai and HealthifyMe
Subscribe To Our Newsletter & Stay Updated
